Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium-coupled neutral amino acid transporter 1 (SLC38A1, SNAT1) is a membrane-bound transporter belonging to the solute carrier (SLC) family 38. It mediates the uptake of small neutral amino acids, with a predominant role in glutamine import. SLC38A1 functions using a sodium-dependent mechanism and is expressed in numerous human tissues such as the brain, testis, placenta, endocrine organs, and gastrointestinal tract. In cancer cells, SNAT1 is often upregulated to meet increased nutrient requirements, thereby supporting proliferation, migration, and invasion, and preventing senescence. SNAT1 also regulates metabolic and signaling pathways, including mTORC1 activation and glutathione synthesis, critical for cell survival and growth. Its inhibition (e.g., via MeAIB) can suppress tumor cell proliferation, highlighting its status as a potential therapeutic target for cancer and other metabolic or neurological diseases
Competitive inhibition of amino acid transport (e.g., MeAIB blocks SNAT1-mediated glutamine and neutral amino acid uptake)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-coupled neutral amino acid transporter 1 (SLC38A1).